Matching-adjusted indirect comparisons of safety and efficacy of acalabrutinib versus other targeted therapies in patients with treatment-naïve chronic lymphocytic leukemiaMatthew S. Davids, Ingo Ringshausen, Catherine Waweru et al.|Leukemia & lymphoma/Leukemia and lymphoma|2021Cited by 16